Kidney cancer working group report

Japanese Journal of Clinical Oncology

Volumn 40, Issue SUPPL. 1, 2010, Pages

  Naito, Seiji ^a   Tomita, Yoshihiko ^b   Rha, Sun Young ^c   Uemura, Hirotsugu ^d   Oya, Mototsugu ^e   Song, He Zhi ^f   Zhong, Li Han ^g   Wahid, Mohamed Ibrahim Bin A ^h  

^a KYUSHU UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c Yonsei University College of Medicine   (South Korea)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f PEKING UNIVERSITY FIRST HOSPITAL   (China)

^g PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^h Malaysian Oncological Society   (Malaysia)

Author keywords

Asia; Guidelines; Racial differences; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER STAGING; DRUG MEGADOSE; HUMAN; INCIDENCE; KIDNEY CANCER; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; NEPHRECTOMY; RISK FACTOR; ASIA; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS;

ASIA; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS;

EID: 77957272015     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq127     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34:193-205.
3. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, IARC CancerBase No. 5. version 2.0. Lyon: IARC Press, 2004.
4. Marugame T, Matsuda T. Comparison of time trends in kidney cancer incidence (1973-97) in East Asia, Europe and USA, from cancer incidence in five continents, Vols IV-VIII. Jpn J Clin Oncol 2008;38:508-9.
5. Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Robins Sadler G. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol 2008;179:1704-8.
6. Kanao K, Mizuno R, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, et al. Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification. J Urol 2009;181:480-5; discussion 485.
7. Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg 2004;93:88-96.
8. Murai M, Oya M. Renal cell carcinoma: etiology, incidence and epidemiology. Curr Opin Urol 2004;14:229-33.
9. Washio M, Mori M, Sakauchi F, Watanabe Y, Ozasa K, Hayashi K, et al. Risk factors for kidney cancer in a Japanese population: findings from the JACC Study. J Epidemiol 2005;15(suppl 2):S203-11.
10. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, et al. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. J Natl Compr Canc Netw 2009;7:618-30.
11. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU Guidelines on Renal Cell Carcinoma: The 2010 Update. Eur Urol 2010; Epub ahead of print July 13.
12. Escudier B, Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(suppl 4):iv81-2.
13. Fujioka T, Obara W. Evidence-based clinical practice guidelines for renal cell carcinoma (Summary-JUA 2007 Edition). Int J Urol 2009;16:339-53.
14. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32.
15. Akaza H, Tsukamoto T, Onishi T, Miki T, Kinouchi T, Naito S. A low-dose combination therapy of interleukin-2 and interferon-α is effective for lung metastasis of renal cell carcinoma: a multicenter open study. Int J Clin Oncol 2006;11:434-40.
16. Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2010;57:317-325.
17. Molina AM, Motzer RJ. Current algorithms and prognostic factors the treatment of metastatic renal cell carcinoma. Clin Genitourin Can 2008;6(suppl 1):S7-S13.
18. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
19. Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010;40:194-202.
20. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
21. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37:755-62.
22. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
23. Sun Y, Na Y, Yu S, Zhang Y, Zhou A, Li N, et al. Sorafenib in the treatment of Chinese patients with advanced renal cell cancer. J Clin Oncol 2008;26(suppl):16127 (abstr).
24. Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin S-J, et al. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 2009;41:67-72.
25. Lee S, Chung HC, Mainwaring P, Ng C, Chang JWC, Kwong P, et al. An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma. Eur J Cancer Suppl 2009;7:428 (abstr).
26. Amantea MA, Houk BE, Bello C. Population pharmacokinetics of sunitinib in Japanese and Western healthy volunteers, solid tumor, metastatic renal cell carcinoma (MRCC) and imatinib-resistant or -intolerant gastrointestinal stromal tumors (GIST) patients. J Clin Oncol 2008;26(suppl):2522 (abstr).
27. Escudier B, Bellmunt J, Negrier S, Melichar B, Bracarda S, Ravaud A, et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009;27(suppl):5020 (abstr).
28. Rini BI, Halabi S, Rosenberg J, Stadler WM, Vaena DA, Atkins JN, et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 2009;27(suppl):LBA5019 (abstr).
29. Hudes G, Motzer RJ, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, Interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
30. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008;372:449-56.